Michaëla Fontenay

The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.

Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.

How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.

Assessed papers (1)

• Integrated analysis of post-transcriptional regulations reveals insights into acute myeloid leukemia.⚑
  2025 L1 32/100 ⚑

1 assessed by us (0 reproduced) · 339 not yet assessed — every PubMed paper on record, linked below.

• Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia ↗

  Journal of Clinical Oncology · 2026 · PMID 41894646
  not yet assessed
• High frequency of <scp>CD95</scp> ⁺ / <scp>CD45RA</scp> ⁻ regulatory T cells defines an immunosuppressive profile associated with <scp>MDS</scp> progression ↗

  British Journal of Haematology · 2026 · PMID 42080308
  not yet assessed
• Focus on the bleeding risk of elderly patients with myelodysplastic syndromes ↗

  Journal of Thrombosis and Haemostasis · 2026 · PMID 42091259
  not yet assessed
• Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower‐risk myelodysplastic syndromes ↗

  HemaSphere · 2025 · PMID 39850648
  not yet assessed
• IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score ↗

  Blood · 2025 · PMID 40561337
  not yet assessed
• FOXP1 contributes to murine hematopoietic stem cell functionality ↗

  Experimental Hematology · 2025 · PMID 40449872
  not yet assessed
• High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidine ↗

  HemaSphere · 2025 · PMID 39760001
  not yet assessed
• Pro-inflammatory role of granzyme K producing bystander CD8 ⁺ T cells in acute myeloid leukemia ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2025
  not yet assessed
• PLENARY SESSION 07: TREATMENT LOW RISK MDS (PART 2) ↗

  Leukemia Research · 2025
  not yet assessed
• RAPID FIRE SESSION 01 ↗

  Leukemia Research · 2025
  not yet assessed
• PARALLEL SESSION 04: PREDICTIVE MODELS FOR RESPONSE IN LOW RISK MDS ↗

  Leukemia Research · 2025
  not yet assessed
• MDS BIOLOGY AND PATHOGENESIS - IMMUNE DEREGULATION / INFLAMMATION ↗

  Leukemia Research · 2025
  not yet assessed
• Targeting ephrin A3 in the bone marrow niche offers a promising therapeutic strategy to impede hematopoietic stem cell maintenance in MDS patients ↗

  Blood · 2025
  not yet assessed
• Integrated analysis of post-transcriptional regulations reveals insights into acute myeloid leukemia⚑

  Communications Biology · 2025 · PMID 41407883
  L1 32/100 ⚑
• Molecular taxonomy of myelodysplastic syndromes and its clinical implications ↗

  Blood · 2024 · PMID 38958467
  not yet assessed
• Molecular and clinical presentation of <i>UBA1</i>-mutated myelodysplastic syndromes ↗

  Blood · 2024 · PMID 38687605
  not yet assessed
• Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation ↗

  Nature Communications · 2024 · PMID 38589367
  not yet assessed
• Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium ↗

  HemaSphere · 2024 · PMID 38756352
  not yet assessed
• Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents ↗

  Blood Cancer Journal · 2024 · PMID 39112451
  not yet assessed
• Along with PaO2/FiO2 ratio and lymphopenia, low HLA-DR monocytes are the only additional parameter that independently predicts the clinical course of undifferentiated SARS-CoV-2 patients in emergency departments ↗

  Journal of Leukocyte Biology · 2024 · PMID 38366559
  not yet assessed
• Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms ↗

  Leukemia · 2024 · PMID 38575672
  not yet assessed
• Monocytes generated by interleukin-6-treated human hematopoietic stem and progenitor cells secrete calprotectin that inhibits erythropoiesis ↗

  iScience · 2024 · PMID 39811665
  not yet assessed
• Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study ↗

  Blood · 2024
  not yet assessed
• A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML) ↗

  Blood · 2024
  not yet assessed
• Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial ↗

  Blood · 2024
  not yet assessed
• Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features ↗

  Blood · 2024
  not yet assessed
• Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers ↗

  Cell Death and Disease · 2024 · PMID 38355585
  not yet assessed
• Biomarkers of COVID-19 short-term worsening: a multiparameter analysis within the prospective multicenter COVIDeF cohort ↗

  European Journal of Emergency Medicine · 2024 · PMID 39292990
  not yet assessed
• Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein ↗

  Cell Death Discovery · 2023 · PMID 36928207
  not yet assessed
• FOXP1 regulates oxidative stress, SIRT1 expression, and resistance to chemotherapies in acute myeloid leukemia cells ↗

  Blood Advances · 2023 · PMID 36930820
  not yet assessed
• Platelet activation and coronavirus disease 2019 mortality: Insights from coagulopathy, antiplatelet therapy and inflammation ↗

  Archives of cardiovascular diseases · 2023 · PMID 36858909
  not yet assessed
• Enhanced fetal hematopoiesis in response to symptomatic SARS-CoV-2 infection during pregnancy ↗

  Communications Medicine · 2023 · PMID 38082066
  not yet assessed
• Physiopathologie des syndromes myélodysplasiques ↗

  Bulletin du Cancer · 2023 · PMID 37423830
  not yet assessed
• Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications ↗

  Blood · 2023
  not yet assessed
• Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry ↗

  Blood · 2023
  not yet assessed
• Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms ↗

  Blood · 2023
  not yet assessed
• PB0236 Bleeding Episode during a Long-Term Anticoagulation with Direct Oral Anticoagulant: An Unusual Revelation of a Severe Factor V Deficiency ↗

  Research and Practice in Thrombosis and Haemostasis · 2023
  not yet assessed
• <i>UBA1</i> Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes ↗

  Blood · 2023
  not yet assessed
• Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients ↗

  Blood · 2023
  not yet assessed
• Somatic Mutations and DNA Hypermethylation at Enhancers and Promoters Identify Distinct Subtypes within Lower-Risk Myelodysplastic Syndromes ↗

  Blood · 2023
  not yet assessed
• Supplementary Procedures, Figures 1-4 from BCL-2 and Mutant NRAS Interact Physically and Functionally in a Mouse Model of Progressive Myelodysplasia ↗

  2023
  not yet assessed
• Supplementary Procedures, Figures 1-4 from BCL-2 and Mutant NRAS Interact Physically and Functionally in a Mouse Model of Progressive Myelodysplasia ↗

  2023
  not yet assessed
• Data from BCL-2 and Mutant NRAS Interact Physically and Functionally in a Mouse Model of Progressive Myelodysplasia ↗

  2023
  not yet assessed
• Data from BCL-2 and Mutant NRAS Interact Physically and Functionally in a Mouse Model of Progressive Myelodysplasia ↗

  2023
  not yet assessed
• Supplementary Tables 1 - 4 from Epigenetic Control of NF-κB-Dependent &lt;i&gt;FAS&lt;/i&gt; Gene Transcription during Progression of Myelodysplastic Syndromes ↗

  2023
  not yet assessed
• Data from Epigenetic Control of NF-κB-Dependent &lt;i&gt;FAS&lt;/i&gt; Gene Transcription during Progression of Myelodysplastic Syndromes ↗

  2023
  not yet assessed
• Data from Epigenetic Control of NF-κB-Dependent &lt;i&gt;FAS&lt;/i&gt; Gene Transcription during Progression of Myelodysplastic Syndromes ↗

  2023
  not yet assessed
• Abstract 6168: Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes ↗

  Cancer Research · 2023
  not yet assessed
• Supplementary Tables 1 - 4 from Epigenetic Control of NF-κB-Dependent &lt;i&gt;FAS&lt;/i&gt; Gene Transcription during Progression of Myelodysplastic Syndromes ↗

  2023
  not yet assessed
• Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES ↗

  Leukemia Research · 2023
  not yet assessed
• Topic: AS03-Health Economics &amp; Outcome Research/AS03a-Cost of care: ARE WE READY TO PERFORM NGS FOR ALL MDS PATIENTS ? ↗

  Leukemia Research · 2023
  not yet assessed
• Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: DNA REPLICATION STRESS DUE TO LOSS OF R-LOOPS IN MYELODYSPLASTIC SYNDROMES WITH SF3B1 MUTATION ↗

  Leukemia Research · 2023
  not yet assessed
• Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells: CALPROTECTIN (S100A8/A9) EFFECTS ON HEALTHY CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS ARE AMPLIFIED IN CHRONIC MYELOID MALIGNANCIES ↗

  Leukemia Research · 2023
  not yet assessed
• S162: LOSS OF HEMATOPOIETIC PROGENITORS HETEROGENEITY IS AN ADVERSE PROGNOSTIC FACTOR IN MYELODYSPLASTIC SYNDROMES ↗

  HemaSphere · 2023
  not yet assessed
• S163: POLYSOME INTERACTOME IN RPS14-DEFICIENT CELLS REVEALS THE INVOLVEMENT OF THE MRNA DECAY MACHINERY IN TRANSLATION SELECTIVITY. ↗

  HemaSphere · 2023
  not yet assessed
• S169: MODULATION OF THE IMMUNE LANDSCAPE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH IMETELSTAT-INDUCED TRANSFUSION INDEPENDENCY ↗

  HemaSphere · 2023
  not yet assessed
• Étude prospective multicentrique de la maladie de Cushing (PHRC COMPLICUSHING) comparant les profils de complications à l’inclusion et résultats préliminaires de leur évolution après traitement à 1 an ↗

  Annales d Endocrinologie · 2023
  not yet assessed
• OC 43.3 Surgery in People with Hemophilia a Receiving Emicizumab Prophylaxis: Real-World Experience from a Single French Reference Center of Hemophilia ↗

  Research and Practice in Thrombosis and Haemostasis · 2023
  not yet assessed
• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms ↗

  Leukemia · 2022 · PMID 35732831
  not yet assessed
• Molecular International Prognostic Scoring System for Myelodysplastic Syndromes ↗

  NEJM Evidence · 2022 · PMID 38319256
  not yet assessed
• Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues ↗

  Cytometry Part B Clinical Cytometry · 2022 · PMID 36537621
  not yet assessed
• Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients ↗

  Blood Cancer Journal · 2022 · PMID 36055992
  not yet assessed
• Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients ↗

  EBioMedicine · 2022 · PMID 35644124
  not yet assessed
• Hematopoietic differentiation is characterized by a transient peak of entropy at a single-cell level ↗

  BMC Biology · 2022 · PMID 35260165
  not yet assessed
• What level of D-dimers can safely exclude pulmonary embolism in COVID-19 patients presenting to the emergency department? ↗

  European Radiology · 2022 · PMID 34994845
  not yet assessed
• RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia ↗

  Leukemia · 2022 · PMID 35354920
  not yet assessed
• <i>Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS</i> ↗

  Blood · 2022
  not yet assessed
• Effets de la dihydroartémisinine sur la régulation du métabolisme du fer et de la ferroptose dans les leucémies aiguës myéloïdes ↗

  2022
  not yet assessed
• DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with <i>SF3B1</i> Mutation ↗

  Blood · 2022
  not yet assessed
• COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects ↗

  Angiogenesis · 2021 · PMID 34184164
  not yet assessed
• APR-246 induces early cell death by ferroptosis in acute myeloid leukemia ↗

  Haematologica · 2021 · PMID 33406814
  not yet assessed
• Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers ↗

  Cell Death and Disease · 2021 · PMID 33707411
  not yet assessed
• Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality ↗

  Angiogenesis · 2021 · PMID 33449299
  not yet assessed
• An IDH1-vitamin C crosstalk drives human erythroid development by inhibiting pro-oxidant mitochondrial metabolism ↗

  Cell Reports · 2021 · PMID 33535038
  not yet assessed
• Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19 ↗

  Journal of Clinical Virology · 2021 · PMID 33965698
  not yet assessed
• Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis ↗

  Cell Death and Differentiation · 2021 · PMID 34230615
  not yet assessed
• Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European <scp>LeukemiaNet</scp> ↗

  Cytometry Part B Clinical Cytometry · 2021 · PMID 34894176
  not yet assessed
• Placental growth factor level in plasma predicts COVID‐19 severity and in‐hospital mortality ↗

  Journal of Thrombosis and Haemostasis · 2021 · PMID 33830623
  not yet assessed
• Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes ↗

  Blood Advances · 2021 · PMID 33890980
  not yet assessed
• Lupus Anticoagulant Single Positivity During the Acute Phase of COVID‐19 Is Not Associated With Venous Thromboembolism or In‐Hospital Mortality ↗

  Arthritis & Rheumatology · 2021 · PMID 33881229
  not yet assessed
• Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDS‐Flow</scp> Cytometry Working Group ↗

  Cytometry Part B Clinical Cytometry · 2021 · PMID 34897979
  not yet assessed
• ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data ↗

  eLife · 2021 · PMID 33929322
  not yet assessed
• Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis ↗

  Blood Cancer Journal · 2021 · PMID 33741892
  not yet assessed
• A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter ↗

  Frontiers in Medicine · 2021 · PMID 34136510
  not yet assessed
• Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin ↗

  Haematologica · 2021 · PMID 34320786
  not yet assessed
• The<i>CADM1</i>tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11 ↗

  Blood Advances · 2021 · PMID 34638130
  not yet assessed
• Pathophysiology of Myelodysplastic Syndromes ↗

  Hemato · 2021
  not yet assessed
• Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis ↗

  medRxiv · 2021
  not yet assessed
• Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes ↗

  Nature Medicine · 2021
  not yet assessed
• Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes ↗

  Nature Medicine · 2021 · PMID 33564192
  not yet assessed
• Hematopoietic differentiation is characterized by a transient peak of entropy at a single cell level ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2021
  not yet assessed
• Author response: ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data ↗

  2021
  not yet assessed
• Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 ↗

  Cell · 2020 · PMID 32810439
  not yet assessed
• Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes ↗

  Nature Medicine · 2020 · PMID 32747829
  not yet assessed
• <i>SF3B1</i>-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS ↗

  Blood · 2020 · PMID 32347921
  not yet assessed
• Immune responses during COVID-19 infection ↗

  OncoImmunology · 2020 · PMID 32939324
  not yet assessed
• p53 activation during ribosome biogenesis regulates normal erythroid differentiation ↗

  Blood · 2020 · PMID 32818241
  not yet assessed
• Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia ↗

  Leukemia · 2020 · PMID 31919471
  not yet assessed
• Pairing MCL‐1 inhibition with venetoclax improves therapeutic efficiency of BH3‐mimetics in AML ↗

  European Journal Of Haematology · 2020 · PMID 32659848
  not yet assessed
• Comprehensive proteomic analysis of murine terminal erythroid differentiation ↗

  Blood Advances · 2020 · PMID 32282884
  not yet assessed
• Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia ↗

  Oncogenesis · 2020 · PMID 33093450
  not yet assessed
• Integrated analyses of translatome and proteome identify the rules of translation selectivity in RPS14-deficient cells ↗

  Haematologica · 2020 · PMID 32327500
  not yet assessed
• Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study ↗

  European Journal of Pharmacology · 2020 · PMID 33249076
  not yet assessed
• Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study ↗

  Leukemia · 2020 · PMID 32684630
  not yet assessed
• The epigenetic regulator RINF (CXXC5) maintains &lt;I&gt;SMAD7&lt;/I&gt; expression in human immature erythroid cells and sustains red blood cell expansion ↗

  Haematologica · 2020 · PMID 33241676
  not yet assessed
• No impact of cancer and plague-relevant <i>FPR1</i> polymorphisms on COVID-19 ↗

  OncoImmunology · 2020 · PMID 33344044
  not yet assessed
• Distinct mutational pattern of myelodysplastic syndromes with and without 5q– treated with lenalidomide ↗

  British Journal of Haematology · 2020 · PMID 32147816
  not yet assessed
• Immunocluster: A Computational Tool to Explore the Immune Profile and Cellular Heterogeneity of Hematological Diseases Using Liquid and Imaging Mass, and Flow Cytometry Data ↗

  Blood · 2020
  not yet assessed
• Multicenter Next-Generation Sequencing Studies between Theory and Practice ↗

  Journal of Molecular Diagnostics · 2020 · PMID 33359455
  not yet assessed
• Coagulation Characterization of Prothrombin 20209C &gt; T Variant: About 27 New Cases ↗

  Thrombosis and Haemostasis · 2020 · PMID 32932543
  not yet assessed
• Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19 ↗

  medRxiv · 2020
  not yet assessed
• Mutation Profiles Identify Distinct Clusters of Lower Risk Myelodysplastic Syndromes with Unique Clinical and Biological Features and Clinical Endpoints ↗

  Blood · 2020
  not yet assessed
• ImmunoCluster: A computational framework for the non-specialist to profile cellular heterogeneity in cytometry datasets ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2020
  not yet assessed
• An IDH1-Vitamin C Crosstalk Drives&amp;nbsp;Human Erythroid Development By&amp;nbsp;Inhibiting Pro-Oxidant Mitochondrial Metabolism ↗

  SSRN Electronic Journal · 2020
  not yet assessed
• TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups ↗

  Leukemia · 2019 · PMID 30635634
  not yet assessed
• Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia ↗

  Leukemia · 2019 · PMID 30894665
  not yet assessed
• Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes ↗

  Blood Advances · 2019 · PMID 31869414
  not yet assessed
• A variant erythroferrone disrupts iron homeostasis in <i>SF3B1</i> -mutated myelodysplastic syndrome ↗

  Science Translational Medicine · 2019 · PMID 31292266
  not yet assessed
• Vitamin K antagonism impairs the bone marrow microenvironment and hematopoiesis ↗

  Blood · 2019 · PMID 31003999
  not yet assessed
• Enhanced Renewal of Erythroid Progenitors in Myelodysplastic Anemia by Peripheral Serotonin ↗

  Cell Reports · 2019 · PMID 30893598
  not yet assessed
• Effect of rivaroxaban and dabigatran on platelet functions: in vitro study ↗

  Thrombosis Research · 2019 · PMID 31678711
  not yet assessed
• Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1‐tube panel strategy for diagnosis and prognosis of patients with MDS ↗

  Cytometry Part B Clinical Cytometry · 2019 · PMID 31498561
  not yet assessed
• The fraction of CD117/c‐KIT‐expressing erythroid precursors predicts ESA response in low‐risk myelodysplastic syndromes ↗

  Cytometry Part B Clinical Cytometry · 2019 · PMID 30963682
  not yet assessed
• Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A real‐life study ↗

  International Journal of Laboratory Hematology · 2019 · PMID 31487115
  not yet assessed
• Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study ↗

  British Journal of Haematology · 2019 · PMID 31215036
  not yet assessed
• TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes ↗

  Blood · 2019
  not yet assessed
• Implications of <i>TP53</i> Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2019
  not yet assessed
• Effect of Rap-536 on MDS PDX-Murine Models with or without SF3B1 Mutation ↗

  Blood · 2019
  not yet assessed
• Effet des anticoagulants oraux directs sur la réactivité plaquettaire ↗

  JMV-Journal de Médecine Vasculaire · 2019
  not yet assessed
• Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents ↗

  EBioMedicine · 2018 · PMID 29728305
  not yet assessed
• Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study ↗

  The Lancet Haematology · 2018 · PMID 30072146
  not yet assessed
• B-cell tumor development in Tet2-deficient mice ↗

  Blood Advances · 2018 · PMID 29581109
  not yet assessed
• Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes ↗

  Haematologica · 2018 · PMID 30287621
  not yet assessed
• <scp>CD</scp>13 expression in B cell malignancies is a hallmark of plasmacytic differentiation ↗

  British Journal of Haematology · 2018 · PMID 30198568
  not yet assessed
• Bone Marrow Niche-Derived Extracellular Matrix-Degrading Enzymes Influence the Progression of B-Cell Acute Lymphoblastic Leukemia ↗

  Blood · 2018
  not yet assessed
• Does being overweight contribute to longer survival rates in myelodysplastic syndrome? ↗

  Haematologica · 2018 · PMID 29572345
  not yet assessed
• Dyserythropoiesis Evaluated by Red Score and Hepcidin/Ferritin Levels Predicts Response to Erythropoietin in Lower Risk Myelodysplastic Syndromes ↗

  SSRN Electronic Journal · 2018
  not yet assessed
• High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells ↗

  Leukemia · 2017 · PMID 28280275
  not yet assessed
• Non-apoptotic functions of caspases in myeloid cell differentiation ↗

  Cell Death and Differentiation · 2017 · PMID 28211870
  not yet assessed
• RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia ↗

  Leukemia · 2017 · PMID 28914261
  not yet assessed
• Dyserythropoiesis of myelodysplastic syndromes ↗

  Current Opinion in Hematology · 2017 · PMID 28072603
  not yet assessed
• Mechanisms underlying the heterogeneity of myelodysplastic syndromes ↗

  Experimental Hematology · 2017 · PMID 29175473
  not yet assessed
• Impact of a pneumatic tube system transport on hemostasis parameters measurement: the experiment of Cochin universitary hospital (AP-HP, Paris, France) ↗

  Annales de biologie clinique · 2017 · PMID 28132949
  not yet assessed
• Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling ↗

  Leukemia · 2017 · PMID 28972593
  not yet assessed
• Ribosome Biogenesis Controls Erythroid Differentiation <i>Via</i> a p53-Dependent Transcriptional Checkpoint and Its Limitation By <i>RPS14</i> Haploinsufficiency Results in Selective Defects in Translation ↗

  Blood · 2017
  not yet assessed
• Impairment of the bone marrow microenvironment and hematopoiesis by warfarin ↗

  Experimental Hematology · 2017
  not yet assessed
• Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents. a Report on 183 Patients ↗

  Blood · 2017
  not yet assessed
• Warfarin Impairs the Bone Marrow Microenvironment and Hematopoiesis Via the Periostin/Integrin β3 Pathway ↗

  Blood · 2017
  not yet assessed
• Lenalidomide-Mediated Erythroid Improvement in Non-Del(5q) Myelodysplastic Syndromes Is Associated with Bone Marrow Immuno-Remodeling ↗

  Blood · 2017
  not yet assessed
• Oxidative Stress in Stem / Progenitor Cells and Specific Antioxidant Response in Bone Marrow from Myelodysplastic Syndrome Patients ↗

  Blood · 2017
  not yet assessed
• DNMT3AR882H mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice ↗

  Leukemia · 2016 · PMID 26876596
  not yet assessed
• Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes? ↗

  Haematologica · 2016 · PMID 27056923
  not yet assessed
• Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes ↗

  Blood · 2016 · PMID 27856460
  not yet assessed
• APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis ↗

  Oncotarget · 2016 · PMID 26910909
  not yet assessed
• Architectural and Functional Heterogeneity of Hematopoietic Stem/Progenitor Cells in Non-Del(5q) Myelodysplastic Syndromes ↗

  Blood · 2016
  not yet assessed
• APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis , on behalf of the Groupe Francophone des Myélodysplasies

  HAL (Le Centre pour la Communication Scientifique Directe) · 2016
  not yet assessed
• Comparison of the Molecular Spectrum of Lenalidomide-Treated Myelodysplastic Syndrome with and without Del(5q) ↗

  Blood · 2016
  not yet assessed
• Proof of Principle for Mutations Monitoring Using Picoliter-Droplet Digital PCR on DNA and Living Cells: Application to Myelodysplastic Syndromes ↗

  Blood · 2016
  not yet assessed
• Gene Expression and Alternative Splicing Datasets Analyses of MDS with Ring Sideroblasts Highlight Alternative Branchpoint Usage in Genes Involved in Iron Metabolism and Erythropoiesis ↗

  Blood · 2016
  not yet assessed
• Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia ↗

  Blood · 2015 · PMID 25852055
  not yet assessed
• Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion ↗

  Leukemia · 2015 · PMID 26500139
  not yet assessed
• Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee ↗

  Blood · 2015
  not yet assessed
• AK2 deficiency compromises the mitochondrial energy metabolism required for differentiation of human neutrophil and lymphoid lineages ↗

  Cell Death and Disease · 2015 · PMID 26270350
  not yet assessed
• Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion ↗

  Blood · 2015 · PMID 26626993
  not yet assessed
• French consensus on myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia: diagnosis, classification and treatment ↗

  Hématologie · 2015
  not yet assessed
• Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters ↗

  Cancer Chemotherapy and Pharmacology · 2015 · PMID 26420236
  not yet assessed
• French consensus on myelodysplasic syndrome and chronic myelomonocytic leukemia: diagnostic, classification and treatment 2015 update by the Myelodysplasia French Group ↗

  Hématologie · 2015
  not yet assessed
• A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM ↗

  Blood · 2015
  not yet assessed
• 104 APG101 (SOLUBLE CD95-FC) IMPROVES BFU-E GROWTH IN LOWER RISK MYELODYSPLASTIC SYNDROME WITH COLLAPSED ERYTHROPOIESIS: A PRECLINICAL STUDY ↗

  Leukemia Research · 2015
  not yet assessed
• 148 CLONAL EVOLUTION OF HEMATOPOIETIC STEM CELL UNDER TREATMENT BY LENALIDOMIDE IN NON DEL(5Q) MDS ↗

  Leukemia Research · 2015
  not yet assessed
• 109 CLINICAL AND MOLECULAR PREDICTORS OF RESPONSE TO ERYTHROPOIESIS STIMULATING AGENTS (ESA) IN LOWER RISK MDS PATIENTS ↗

  Leukemia Research · 2015
  not yet assessed
• 159 CSNK1A1 IS NORMALLY EXPRESSED AND UNMUTATED IN MDS PATIENTS WITHOUT DEL(5Q) BEFORE AND UNDER TREATMENT WITH LENALIDOMIDE ↗

  Leukemia Research · 2015
  not yet assessed
• Pegylated liposomal doxorubicin-induced palmar plantar erythrodyesthesia: Identification of risks factors. ↗

  Journal of Clinical Oncology · 2015
  not yet assessed
• Figure S1 - Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket ↗

  Figshare · 2015
  not yet assessed
• HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia ↗

  Nature · 2014 · PMID 25156257
  not yet assessed
• A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages ↗

  Leukemia · 2014 · PMID 24434863
  not yet assessed
• Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy ↗

  Cytometry Part B Clinical Cytometry · 2014 · PMID 25399680
  not yet assessed
• Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy ↗

  Cytometry Part B Clinical Cytometry · 2014 · PMID 25349085
  not yet assessed
• NPM1 Expression Level and a CRBN Polymorphism Are Able to Predict the Rate of Response to Lenalidomide in Non Del(5q) Lower Risk MDS Patients Resistant to Erythropoiesis-Stimulating Agents: The GFM Experience ↗

  Blood · 2014
  not yet assessed
• TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee ↗

  Blood · 2014
  not yet assessed
• Collapse of Ribosome Biogenesis Induces Rapid Erythroblast Differentiation ↗

  Blood · 2014
  not yet assessed
• Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia ↗

  Journal of Clinical Oncology · 2013 · PMID 23690417
  not yet assessed
• Clonal architecture of chronic myelomonocytic leukemias ↗

  Blood · 2013 · PMID 23319568
  not yet assessed
• BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders ↗

  Blood · 2013 · PMID 24047651
  not yet assessed
• SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias ↗

  Leukemia · 2013 · PMID 23443343
  not yet assessed
• Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes ↗

  Leukemia · 2013 · PMID 23765225
  not yet assessed
• Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine ↗

  Leukemia · 2013 · PMID 24192812
  not yet assessed
• STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model ↗

  Haematologica · 2013 · PMID 23872306
  not yet assessed
• Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia ↗

  Leukemia · 2013 · PMID 23774674
  not yet assessed
• A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q) ↗

  Leukemia · 2013 · PMID 23434730
  not yet assessed
• Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket ↗

  PLoS ONE · 2013 · PMID 23637779
  not yet assessed
• Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification ↗

  Leukemia Research · 2013 · PMID 23453284
  not yet assessed
• Epigenetic Control of NF-κB-Dependent <i>FAS</i> Gene Transcription during Progression of Myelodysplastic Syndromes ↗

  Molecular Cancer Research · 2013 · PMID 23604035
  not yet assessed
• Use of the 46/1 haplotype to model JAK2V617F clonal architecture in PV patients: clonal evolution and impact of IFNα treatment ↗

  Leukemia · 2013 · PMID 24150219
  not yet assessed
• A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO. ↗

  Journal of Clinical Oncology · 2013
  not yet assessed
• P-023 Incidence and prognostic value of TP53 mutations in IPSS low and INT 1 (lower risk) MDS with del 5q ↗

  Leukemia Research · 2013
  not yet assessed
• P-004 SETBP1 mutations in 658 patients with myeldodysplastic syndromes, chronic myelomonocytic leukemia and secondary AML ↗

  Leukemia Research · 2013
  not yet assessed
• P-233 Promoter methylation abrogates of NFκB-mediated FAS gene transcription during progression of myelodysplastic syndromes ↗

  Leukemia Research · 2013
  not yet assessed
• P-133 A single nucleotide polymorphism in CRBN gene as a biomarker of response to treatment with lenalidomide in MDS without del5q ↗

  Leukemia Research · 2013
  not yet assessed
• O-007 BCOR and BCORL1 mutations in myelodysplasia: Prevalence, prognosis and clonal hierarchy ↗

  Leukemia Research · 2013
  not yet assessed
• P-071 Flow cytometric detection of dyserythropoiesis is a sensitive and powerful tool for myelodysplastic syndrome diagnosis ↗

  Leukemia Research · 2013
  not yet assessed
• Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes ↗

  Blood · 2012 · PMID 22343920
  not yet assessed
• Duration of Postoperative Fibrinolysis after Total Hip or Knee Replacement: A Laboratory Follow-up Study ↗

  Thrombosis Research · 2012 · PMID 23195143
  not yet assessed
• Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis ↗

  Human Mutation · 2012 · PMID 22553128
  not yet assessed
• Heat shock proteins in hematopoietic malignancies ↗

  Experimental Cell Research · 2012 · PMID 22652452
  not yet assessed
• A short Gfi-1B isoform controls erythroid differentiation by recruiting the LSD1–CoREST complex through the dimethylation of its SNAG domain ↗

  Journal of Cell Science · 2012 · PMID 22399799
  not yet assessed
• Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies ↗

  Leukemia · 2012 · PMID 22484420
  not yet assessed
• Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML ↗

  Leukemia · 2012 · PMID 22743624
  not yet assessed
• Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia ↗

  Oncotarget · 2012 · PMID 23327988
  not yet assessed
• Metabolites of Tryptophan Catabolism Are Elevated in Sera of Patients with Myelodysplastic Syndromes and Inhibit Hematopoietic Progenitor Amplification ↗

  Blood · 2012
  not yet assessed
• Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML) ↗

  Blood · 2012
  not yet assessed
• Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes ↗

  Leukemia Research · 2012 · PMID 23153525
  not yet assessed
• Sustained Leukemia-Free State and Molecular Response to Sorafenib in a Patient With Chronic Myelomonocytic Leukemia in Transformation Driven by Homozygous FLT3-ITD Malignant Hematopoiesis ↗

  Clinical Lymphoma Myeloma & Leukemia · 2012 · PMID 23246161
  not yet assessed
• Mutations des gènes impliqués dans l’épissage dans les hémopathies malignes humaines ↗

  médecine/sciences · 2012 · PMID 22642991
  not yet assessed
• Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q. ↗

  Blood · 2012
  not yet assessed
• Targeted Therapy in CMML: Complete Molecular Response to Sorafenib in a Patient with a FLT3-ITD Malignant Hematopoiesis ↗

  Blood · 2012
  not yet assessed
• Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the GFM and FISM). ↗

  Blood · 2012
  not yet assessed
• Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML) ↗

  Blood · 2012
  not yet assessed
• Retard de croissance intra-utérin et thrombophilie ↗

  Elsevier eBooks · 2012
  not yet assessed
• Heterogeneous Genotypes Support Common Phenotypic Features in Myelodysplastic Syndromes ↗

  AACR Education book · 2012
  not yet assessed
• NRAS:BCL-2 Complex Localization Determines Anti-Apoptotic Features Associated with Progressive Disease in Myelodysplastic Syndromes (MDS) ↗

  Blood · 2012
  not yet assessed
• Epigenetic Down-Regulation of NFkB-Mediated FAS Gene Transcription During Progression of Myelodysplastic Syndromes ↗

  Blood · 2012
  not yet assessed
• BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes ↗

  Blood · 2012
  not yet assessed
• Liste des auteurs ↗

  Elsevier eBooks · 2012
  not yet assessed
• TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis ↗

  Cancer Cell · 2011 · PMID 21723201
  not yet assessed
• Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias ↗

  Leukemia · 2011 · PMID 21494260
  not yet assessed
• Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial ↗

  Blood · 2011 · PMID 21828134
  not yet assessed
• Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy ↗

  Haematologica · 2011 · PMID 21228037
  not yet assessed
• SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications ↗

  Leukemia · 2011 · PMID 22064355
  not yet assessed
• Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes ↗

  Blood · 2011 · PMID 22160620
  not yet assessed
• Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases ↗

  Leukemia Research · 2011 · PMID 21396711
  not yet assessed
• TET2 mutations in secondary acute myeloid leukemias: a French retrospective study ↗

  Haematologica · 2011 · PMID 21508122
  not yet assessed
• TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis ↗

  Cancer Cell · 2011
  not yet assessed
• 306 Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias ↗

  Leukemia Research · 2011
  not yet assessed
• 44 FAS gene expression is epigenetically regulated and predicts the responsiveness to azacitidine in high-risk myelodysplastic syndromes ↗

  Leukemia Research · 2011
  not yet assessed
• Syndromes myélodysplasiques : actualités clinico-biologiques ↗

  Revue Francophone des Laboratoires · 2011
  not yet assessed
• New variant of unclassified congenital dyserythropoietic anaemia: the concept of the erythroid regulator? ↗

  British Journal of Haematology · 2011 · PMID 22077468
  not yet assessed
• IDH1/2, TET2 and DNMT3A Mutations Are Not Mutually Exclusive in Secondary Acute Myeloid Leukemias, ↗

  Blood · 2011
  not yet assessed
• Point mutations in myelodysplastic syndromes. ↗

  PubMed · 2011 · PMID 21992131
  not yet assessed
• 291 Prognostic impact of JAK2V617F mutation in MDS: a matched case control study ↗

  Leukemia Research · 2011
  not yet assessed
• 305 TET2 and IDH1/2 mutations in secondary acute myeloid leukemias: A French retrospective study ↗

  Leukemia Research · 2011
  not yet assessed
• 239 NF-κB regulates FAS gene expression in myelodysplastic syndromes ↗

  Leukemia Research · 2011
  not yet assessed
• Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms ↗

  Leukemia · 2010 · PMID 20376084
  not yet assessed
• Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission ↗

  Blood · 2010 · PMID 20489055
  not yet assessed
• Genetic typing of <i>CBL</i>, <i>ASXL1</i>, <i>RUNX1</i>, <i>TET2</i> and <i>JAK2</i> in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia ↗

  British Journal of Haematology · 2010 · PMID 20955399
  not yet assessed
• p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes ↗

  Haematologica · 2010 · PMID 20823131
  not yet assessed
• Presence of TET2 Mutation Predicts A Higher Response Rate to Azacitidine In MDS and AML Post MDS ↗

  Blood · 2010
  not yet assessed
• Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice ↗

  Thrombosis and Haemostasis · 2010 · PMID 20539905
  not yet assessed
• FAS Gene Expression Is Epigenetically Regulated and Predicts the Responsiveness to Azacitidine In High-Risk Myelodysplastic Syndromes ↗

  Blood · 2010
  not yet assessed
• [Myeloproliferative/myelodysplastic syndromes]. ↗

  PubMed · 2010 · PMID 21425542
  not yet assessed
• Prévalence de la thrombophilie dans une cohorte de 2617 femmes : influence de la localisation distale ou proximale de la thrombose veineuse profonde ↗

  Journal des Maladies Vasculaires · 2010
  not yet assessed
• Prognostic Impact of JAK2V617F Mutation In MDS: a Matched Case Control Study ↗

  Blood · 2010
  not yet assessed
• Mutation in <i>TET2</i> in Myeloid Cancers ↗

  New England Journal of Medicine · 2009 · PMID 19474426
  not yet assessed
• TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) ↗

  Blood · 2009 · PMID 19666869
  not yet assessed
• TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia ↗

  Haematologica · 2009 · PMID 19797729
  not yet assessed
• Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia ↗

  Blood · 2009 · PMID 19864642
  not yet assessed
• Fetal Intracerebral Hemorrhage in Familial Thrombophilia ↗

  Pediatric Neurology · 2009 · PMID 19748050
  not yet assessed
• Mutations du gène<i>TET2</i>dans les hémopathies myéloïdes humaines ↗

  médecine/sciences · 2009 · PMID 19849974
  not yet assessed
• Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML). ↗

  Blood · 2009
  not yet assessed
• Physiopathologie des syndromes myélodysplasiques ↗

  Revue Francophone des Laboratoires · 2009
  not yet assessed
• ABT 737 BCL-2 INHIBITOR TARGETS LEUKEMIC STEM CELLS IN MOUSE MODELS OF MYELOID (PRE)LEUKAEMIA

  Research Portal (King's College London) · 2009
  not yet assessed
• C034 Biological factors of response to erythropoiesis-stimulating agents in low/int-1 grade MDS ↗

  Leukemia Research · 2009
  not yet assessed
• P051 TET2 is a tumor suppressor gene targeted in myeloid disorders ↗

  Leukemia Research · 2009
  not yet assessed
• C020 Prevalence of TET2 mutations in MDS ↗

  Leukemia Research · 2009
  not yet assessed
• Role of GATA-1 and HSP70 in the Dyserythropoiesis of Early Myelodysplastic Syndromes. ↗

  Blood · 2009
  not yet assessed
• P-ERK1/2 Is a Predictive Factor of Response to ESA Treatment in Myelodysplastic Syndromes. ↗

  Blood · 2009
  not yet assessed
• Heat shock proteins: essential proteins for apoptosis regulation ↗

  Journal of Cellular and Molecular Medicine · 2008 · PMID 18266962
  not yet assessed
• NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity ↗

  Blood · 2008 · PMID 18984862
  not yet assessed
• Activation of PAK1/2 during the shedding of platelet microvesicles ↗

  Blood Coagulation & Fibrinolysis · 2008 · PMID 20523167
  not yet assessed
• Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum ↗

  Leukemia · 2008 · PMID 18615109
  not yet assessed
• TET2 Is a Novel Tumor Suppressor Gene Inactivated in Myeloproliferative Neoplasms: Identification of a Pre-JAK2 V617F Event ↗

  Blood · 2008
  not yet assessed
• Apoptotic pathways to death in myelodysplastic syndromes ↗

  Haematologica · 2008 · PMID 18757848
  not yet assessed
• Syndromes myélodysplasiques avec délétion du bras long du chromosome 5 ↗

  Hématologie · 2008
  not yet assessed
• Characteristics and Outcome of MDS with Isolated Del 20q: The GFM Experience in 64 Cases. ↗

  Blood · 2008
  not yet assessed
• BCL-2 and Mutant NRAS Interact Physically and Functionally in a Mouse Model of Progressive Myelodysplasia ↗

  Cancer Research · 2007 · PMID 18089795
  not yet assessed
• A role for caspases in the differentiation of erythroid cells and macrophages ↗

  Biochimie · 2007 · PMID 17905508
  not yet assessed
• Los nuevos antitrombóticos

  Redalyc (Universidad Autónoma del Estado de México) · 2007
  not yet assessed
• P030 A role for the endoplasmic reticulum in the apoptosis of erythroid precursors in low risk myelodysplastic syndromes ↗

  Leukemia Research · 2007
  not yet assessed
• P071 Endoplasmic reticulum gene expression profile of erythroid progenitors in low risk myelodysplastic syndromes ↗

  Leukemia Research · 2007
  not yet assessed
• Fas-Dependent Apoptosis in Early MDS Erythroid Precursors Involves Endoplasmic Reticulum. ↗

  Blood · 2007
  not yet assessed
• Endoplasmic reticulum gene expression profile of erythroid progenitors in low risk myelodysplastic syndromes

  Oxford University Research Archive (ORA) (University of Oxford) · 2007
  not yet assessed
• Caspase-8 prevents sustained activation of NF-κB in monocytes undergoing macrophagic differentiation ↗

  Blood · 2006 · PMID 17047155
  not yet assessed
• Mitochondria in hematopoiesis and hematological diseases ↗

  Oncogene · 2006 · PMID 16892088
  not yet assessed
• Identification of Proteins Cleaved Downstream of Caspase Activation in Monocytes Undergoing Macrophage Differentiation ↗

  Journal of Biological Chemistry · 2006 · PMID 16636047
  not yet assessed
• Erythropoiesis Abnormalities Contribute to Early-Onset Anemia in Patients with Septic Shock ↗

  American Journal of Respiratory and Critical Care Medicine · 2006 · PMID 16574939
  not yet assessed
• Both the Endoplasmic Reticulum and the Mitochondria Are Involved in Apoptosis of Erythroid Precursors in Low Grade Myelodysplastic Syndromes. ↗

  Blood · 2006
  not yet assessed
• Experience with on-site ROTEM® thromboelastometry monitoring of coagulation during liver transplantation ↗

  European Journal of Anaesthesiology · 2006
  not yet assessed
• Vital functions for lethal caspases ↗

  Oncogene · 2005 · PMID 16079910
  not yet assessed
• Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD ↗

  Blood · 2005 · PMID 15677568
  not yet assessed
• Mutation in RAP1 is a rare event in myelodysplastic syndromes ↗

  Leukemia · 2005 · PMID 16118622
  not yet assessed
• Reply to ‘hRap1B-retro: a novel human processed Rap1B gene blurs the picture?’ by Zemojtel et al ↗

  Leukemia · 2005 · PMID 16307014
  not yet assessed
• P-48 rap1b point mutations homologousto activating RAS mutations are uncommon during MDS leukemic transformation ↗

  Leukemia Research · 2005
  not yet assessed
• Expression of two type 2N von Willebrand disease mutations identified in exon 18 of von Willebrand factor gene ↗

  British Journal of Haematology · 2004 · PMID 15461624
  not yet assessed
• Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation ↗

  Blood · 2003 · PMID 12506011
  not yet assessed
• Cdc42/Rac1-dependent activation of the p21-activated kinase (PAK) regulates human platelet lamellipodia spreading: implication of the cortical-actin binding protein cortactin ↗

  Blood · 2002 · PMID 12453877
  not yet assessed
• In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis ↗

  Blood · 2002 · PMID 11861273
  not yet assessed
• Physiopathologie des syndromes myélodysplasiques ↗

  Pathologie Biologie · 2002 · PMID 12085671
  not yet assessed
• Flow cytometry detection of platelet procoagulation activity and microparticles in patients with unstable angina treated by percutaneous coronary angioplasty and stent implantation. ↗

  PubMed · 2001 · PMID 11583308
  not yet assessed
• Flow Cytometry Detection of Platelet Procoagulant Activity and Microparticles in Patients with Unstable Angina Treated by Percutaneous Coronary Angioplasty and Stent Implantation ↗

  Thrombosis and Haemostasis · 2001
  not yet assessed
• Thrombopoietin stimulates cortactin translocation to the cytoskeleton independently of tyrosine phosphorylation ↗

  Biochemical Journal · 2001 · PMID 11389697
  not yet assessed
• Increased apoptosis in mononucleated cells but not in CD34+ cells in blastic forms of myelodysplastic syndromes ↗

  The Hematology Journal · 2001
  not yet assessed
• Increased apoptosis in mononucleated cells but not in CD34+ cells in blastic forms of myelodysplastic syndromes. ↗

  PubMed · 2001 · PMID 11424000
  not yet assessed
• Thrombopoietin stimulates cortactin translocation to the cytoskeleton independently of tyrosine phosphorylation ↗

  Biochemical Journal · 2001
  not yet assessed
• Activity of the caspase-3/CPP32 enzyme is increased in “early stage” myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro ↗

  Experimental Hematology · 2000 · PMID 10907640
  not yet assessed
• In Response: ↗

  Experimental Hematology · 2000
  not yet assessed
• Megakaryocyte Growth and Development Factor-Induced Proliferation and Differentiation Are Regulated by the Mitogen-Activated Protein Kinase Pathway in Primitive Cord Blood Hematopoietic Progenitors ↗

  Blood · 1999 · PMID 10477685
  not yet assessed
• Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction ↗

  British Journal of Haematology · 1999 · PMID 10460607
  not yet assessed
• Megakaryocyte Growth and Development Factor-Induced Proliferation and Differentiation Are Regulated by the Mitogen-Activated Protein Kinase Pathway in Primitive Cord Blood Hematopoietic Progenitors ↗

  Blood · 1999
  not yet assessed
• Aplastic Anemia Responsive to Cyclosporine Complicating the Evolution of Polycythemia Vera ↗

  Leukemia & lymphoma/Leukemia and lymphoma · 1999 · PMID 10342591
  not yet assessed
• Microvésiculation plaquettaire et réarrangements du cytosquelette d’actine

  Hématologie · 1999
  not yet assessed
• From platelet shape change to microvesiculation : the actin cytoskeleton rearrangements

  Hématologie · 1999
  not yet assessed
• Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia ↗

  Leukemia Research · 1998 · PMID 9678719
  not yet assessed
• Thrombopoietin activates human platelets and induces tyrosine phosphorylation of p80/85 cortactin. ↗

  PubMed · 1998 · PMID 9459347
  not yet assessed
• Thrombopoietin Activates Human Platelets and Induces Tyrosine Phosphorylation of p80/85 Cortactin ↗

  Thrombosis and Haemostasis · 1998
  not yet assessed
• Lack of evidence of an association between HHV-8 and multiple myeloma ↗

  Leukemia · 1998 · PMID 9823963
  not yet assessed
• Fluorescence in situ hybridization on methylcellulose cultured hematopoietic stem cells from myelodysplastic syndromes ↗

  Cancer Genetics and Cytogenetics · 1998 · PMID 9460494
  not yet assessed
• Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes ↗

  Leukemia · 1997 · PMID 9177438
  not yet assessed
• Expression of the transcription factor Evi-1 in human erythroleukemia cell lines and in leukemias ↗

  Hematology and Cell Therapy · 1997 · PMID 9088932
  not yet assessed
• Unusual occurrence of spontaneous haematomas in three asymptomatic HIV-infected haemophilia patients a few days after the onset of ritonavir treatment. ↗

  PubMed · 1997 · PMID 9147435
  not yet assessed
• [Abnormalities of the expression of cytokines and their receptors in myelodysplastic syndromes]. ↗

  PubMed · 1997 · PMID 9404481
  not yet assessed
• 95 Serum levels of thrombopoietin (TPO) In myelodysplasias ↗

  Leukemia Research · 1997
  not yet assessed
• 101 Apoptosis and fas antigen (CD95) expression in myclodysplasia ↗

  Leukemia Research · 1997
  not yet assessed
• 86 Effects of rHumegakaryocyte growth and development factor (rHuMGDF) on in vitro proliferation of megakaryocyte progenitors in myelodysplastic syndromes (MDS) ↗

  Leukemia Research · 1997
  not yet assessed
• 85 Identification of a group of thrombocytopenic MDS patients. Candidate for in vivo treatment with PEG-rHuMGDF ↗

  Leukemia Research · 1997
  not yet assessed
• Transforming growth factor <i>β</i> 1 inhibits mitogen-activated protein kinase induced by basic fibroblast growth factor in smooth muscle cells ↗

  Biochemical Journal · 1996 · PMID 8645201
  not yet assessed
• Thrombocytemia and abnormal megakaryopoiesis associated with abnormality of chromosome 1p34 in myelodysplastic syndromes. ↗

  PubMed · 1996 · PMID 8892668
  not yet assessed
• Increased proliferation of bone marrow-derived fibroblasts in primitive hypertrophic osteoarthropathy with severe myelofibrosis ↗

  Blood · 1995 · PMID 7756654
  not yet assessed
• Thrombopoietin is not responsible for the thrombocytosis observed in patients with acute myeloid leukemias and the 3q21q26 syndrome ↗

  British Journal of Haematology · 1995 · PMID 8547088
  not yet assessed
• Transforming growth factor-<i>β</i> 1 increases internalization of basic fibroblast growth factor by smooth muscle cells: implication of cell-surface heparan sulphate proteoglycan endocytosis ↗

  Biochemical Journal · 1995 · PMID 7487873
  not yet assessed
• Mecanismes inhibiteurs induits par le transforming growth factor-beta dans la transduction du signal du platelet-derived growth factor et du fibroblast growth factor basique

  1995
  not yet assessed
• Evidence for Rap1 in vascular smooth muscle cells ↗

  FEBS Letters · 1994 · PMID 8143870
  not yet assessed
• Phosphorylation of Rap1GAP during the Cell Cycle ↗

  Biochemical and Biophysical Research Communications · 1994 · PMID 8048970
  not yet assessed
• Increased mitogenic activity of scleroderma serum: inhibitory effect of human recombinant interferon-gamma. ↗

  Annals of the Rheumatic Diseases · 1994 · PMID 7826142
  not yet assessed
• Inhibition of platelet-derived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostins ↗

  Experimental Cell Research · 1992 · PMID 1312007
  not yet assessed
• Transforming growth factor‐β1 inhibitory effect of platelet‐derived growth factor‐‐induced signal transduction on human bone marrow fibroblasts: Possible involvement of protein phosphatases ↗

  Journal of Cellular Physiology · 1992 · PMID 1324246
  not yet assessed
• Le PGDF (platelet derived growth factor) et ses implications en pathologie humaine ↗

  médecine/sciences · 1991
  not yet assessed
• T cell receptor delta gene rearrangements occur predominantly in immature myeloid leukemias exhibiting lineage promiscuity. ↗

  PubMed · 1990 · PMID 2137546
  not yet assessed
• [HLA and auto-immune thrombopenic purpura in an HIV-positive population]. ↗

  PubMed · 1989 · PMID 2648270
  not yet assessed
• Etude multiparamétrique de 60 cas de leucémies aigües myeloblastiques : identification d'une sous-population présentant un réarrangement de la chaine delta du récepteur T pour l'antigène

  1989
  not yet assessed
• [Study of the plasma and urinary steroids in the course of treatment of anovulation by human urinary gonadotropins. Presence of estradiol in increased quantities in peripheral vein in the blood in period of follicular maturation]. ↗

  PubMed · 1968 · PMID 4970484
  not yet assessed